Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25519506 | 0.85 | PRKCA (0.33) | PRKCACYP4F2CYP4A11HMGCRMMP8 | |
| SCHEMBL14827375 | 0.84 | HMGCR (0.38) | PRKCACYP4F2CYP4A11HMGCRMMP8 | |
| SCHEMBL2681051 | 0.84 | PRKCA (0.35) | PRKCACYP4F2CYP4A11HMGCRMMP8 | |
| SCHEMBL2681020 | 0.83 | TSHR (0.42) | PRKCACYP4F2CYP4A11HMGCRMMP8 | |
| SCHEMBL14769605 | 0.83 | PRKCA (0.37) | PRKCACYP4F2CYP4A11HMGCRMMP8 | |
| SCHEMBL22601580 | 0.82 | CYP4F2 (0.34) | PRKCACYP4F2CYP4A11HMGCR | |
| SCHEMBL6380226 | 0.82 | MAPT (0.43) | PRKCACYP4F2CYP4A11HMGCRMMP8 | |
| SCHEMBL15451564 | 0.80 | CYP4F2 (0.33) | PRKCACYP4F2CYP4A11 | |
| SCHEMBL8988305 | 0.80 | MAPT (0.42) | PRKCACYP4F2CYP4A11HMGCRMMP8 | |
| SCHEMBL14195308 | 0.80 | HMGCR (0.35) | PRKCACYP4F2CYP4A11HMGCRMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | PRKCA 204/4885CYP4F2 4059/4885CYP4A11 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.